Circulating immunoglobulin-bound transforming growth factor β at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells

M. Harada, K. Tatsugami, M. Nomoto, K. Nomoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In order to elucidate the mechanisms by which tumour-specific CD4+ T-cell responses are impaired during tumour development, an attempt was made to identify factors which impair CD4+ T-cell responses at a late tumour-bearing stage. Plasma from mice bearing B16 melanoma for 30 days (plasma d30) showed a more profound immunosuppressive effect on the in vitro proliferation of unrelated antigen-specific CD4+ T cells in the presence of both antigen and antigen-presenting cells (APC) than plasma from naïve mice. The level of plasma transforming growth factor (TGF)-β was elevated in mice bearing B16 melanoma for 30 days compared with naïve mice, and the suppressive effect of plasma d30 was partially diminished by the neutralization of TGF-β. Interestingly, immunoglobulin (IgG)-bound TGF-β, but not IgG-unbound TGF-β, in plasma d30 was suggested to be responsible for the immuno-suppressive activity. In addition, no suppressive effect of plasma d30 was observed when antigen was added as a class II peptide, thus suggesting that the impaired proliferation of CD4+ T cells in the presence of plasma d30 was due to a dysfunction of antigen uptake/processing by APC. Furthermore, dissociation between IgG and TGF-β resulted in a loss of the suppressive activity of plasma d30. Taken together, these results suggest that circulating IgG-bound TGF-β is, at least in part, responsible for the impaired responses of CD4+ T cells at the late tumour-bearing stage by suppressing antigen uptake/ processing by APC.

Original languageEnglish
Pages (from-to)204-212
Number of pages9
JournalClinical and Experimental Immunology
Volume128
Issue number2
DOIs
Publication statusPublished - May 30 2002

Fingerprint

Transforming Growth Factors
Immunoglobulins
T-Lymphocytes
Antigens
Neoplasms
Antigen-Presenting Cells
Experimental Melanomas
Antigen Presentation
CD4 Antigens
Immunosuppressive Agents
Peptides

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Circulating immunoglobulin-bound transforming growth factor β at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells. / Harada, M.; Tatsugami, K.; Nomoto, M.; Nomoto, K.

In: Clinical and Experimental Immunology, Vol. 128, No. 2, 30.05.2002, p. 204-212.

Research output: Contribution to journalArticle

@article{6046f65de6144b8f999a3407abdd257e,
title = "Circulating immunoglobulin-bound transforming growth factor β at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells",
abstract = "In order to elucidate the mechanisms by which tumour-specific CD4+ T-cell responses are impaired during tumour development, an attempt was made to identify factors which impair CD4+ T-cell responses at a late tumour-bearing stage. Plasma from mice bearing B16 melanoma for 30 days (plasma d30) showed a more profound immunosuppressive effect on the in vitro proliferation of unrelated antigen-specific CD4+ T cells in the presence of both antigen and antigen-presenting cells (APC) than plasma from na{\"i}ve mice. The level of plasma transforming growth factor (TGF)-β was elevated in mice bearing B16 melanoma for 30 days compared with na{\"i}ve mice, and the suppressive effect of plasma d30 was partially diminished by the neutralization of TGF-β. Interestingly, immunoglobulin (IgG)-bound TGF-β, but not IgG-unbound TGF-β, in plasma d30 was suggested to be responsible for the immuno-suppressive activity. In addition, no suppressive effect of plasma d30 was observed when antigen was added as a class II peptide, thus suggesting that the impaired proliferation of CD4+ T cells in the presence of plasma d30 was due to a dysfunction of antigen uptake/processing by APC. Furthermore, dissociation between IgG and TGF-β resulted in a loss of the suppressive activity of plasma d30. Taken together, these results suggest that circulating IgG-bound TGF-β is, at least in part, responsible for the impaired responses of CD4+ T cells at the late tumour-bearing stage by suppressing antigen uptake/ processing by APC.",
author = "M. Harada and K. Tatsugami and M. Nomoto and K. Nomoto",
year = "2002",
month = "5",
day = "30",
doi = "10.1046/j.1365-2249.2002.01806.x",
language = "English",
volume = "128",
pages = "204--212",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Circulating immunoglobulin-bound transforming growth factor β at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells

AU - Harada, M.

AU - Tatsugami, K.

AU - Nomoto, M.

AU - Nomoto, K.

PY - 2002/5/30

Y1 - 2002/5/30

N2 - In order to elucidate the mechanisms by which tumour-specific CD4+ T-cell responses are impaired during tumour development, an attempt was made to identify factors which impair CD4+ T-cell responses at a late tumour-bearing stage. Plasma from mice bearing B16 melanoma for 30 days (plasma d30) showed a more profound immunosuppressive effect on the in vitro proliferation of unrelated antigen-specific CD4+ T cells in the presence of both antigen and antigen-presenting cells (APC) than plasma from naïve mice. The level of plasma transforming growth factor (TGF)-β was elevated in mice bearing B16 melanoma for 30 days compared with naïve mice, and the suppressive effect of plasma d30 was partially diminished by the neutralization of TGF-β. Interestingly, immunoglobulin (IgG)-bound TGF-β, but not IgG-unbound TGF-β, in plasma d30 was suggested to be responsible for the immuno-suppressive activity. In addition, no suppressive effect of plasma d30 was observed when antigen was added as a class II peptide, thus suggesting that the impaired proliferation of CD4+ T cells in the presence of plasma d30 was due to a dysfunction of antigen uptake/processing by APC. Furthermore, dissociation between IgG and TGF-β resulted in a loss of the suppressive activity of plasma d30. Taken together, these results suggest that circulating IgG-bound TGF-β is, at least in part, responsible for the impaired responses of CD4+ T cells at the late tumour-bearing stage by suppressing antigen uptake/ processing by APC.

AB - In order to elucidate the mechanisms by which tumour-specific CD4+ T-cell responses are impaired during tumour development, an attempt was made to identify factors which impair CD4+ T-cell responses at a late tumour-bearing stage. Plasma from mice bearing B16 melanoma for 30 days (plasma d30) showed a more profound immunosuppressive effect on the in vitro proliferation of unrelated antigen-specific CD4+ T cells in the presence of both antigen and antigen-presenting cells (APC) than plasma from naïve mice. The level of plasma transforming growth factor (TGF)-β was elevated in mice bearing B16 melanoma for 30 days compared with naïve mice, and the suppressive effect of plasma d30 was partially diminished by the neutralization of TGF-β. Interestingly, immunoglobulin (IgG)-bound TGF-β, but not IgG-unbound TGF-β, in plasma d30 was suggested to be responsible for the immuno-suppressive activity. In addition, no suppressive effect of plasma d30 was observed when antigen was added as a class II peptide, thus suggesting that the impaired proliferation of CD4+ T cells in the presence of plasma d30 was due to a dysfunction of antigen uptake/processing by APC. Furthermore, dissociation between IgG and TGF-β resulted in a loss of the suppressive activity of plasma d30. Taken together, these results suggest that circulating IgG-bound TGF-β is, at least in part, responsible for the impaired responses of CD4+ T cells at the late tumour-bearing stage by suppressing antigen uptake/ processing by APC.

UR - http://www.scopus.com/inward/record.url?scp=0036094564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036094564&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.2002.01806.x

DO - 10.1046/j.1365-2249.2002.01806.x

M3 - Article

C2 - 12041507

AN - SCOPUS:0036094564

VL - 128

SP - 204

EP - 212

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -